Wan Yuntao: The Path of Clinical Science Manager of a Biological Experimenter.

Guide: There is a kind of happiness in the challenging and fun work life to look forward to an uncertain future.
's interest and courage determine career development - leaving the lab for clinical project management, leaving the Japanese-based New Base Company to return home to join Shanghai Roche, and coming to Bayer to participate in higher strategic decision-making in research and development, giving up comfort and stability again and again to follow your heart.
a happiness is to look forward to an uncertain future in a challenging and fun work life.
- Wan Yuntao leads multi-sector operations in Bayer China, including medical, clinical pharmacology, biomarkers and clinical programs, responsible for early and clinical pharmacological trials in China and asia Pacific in a wide range of areas, including oncology, cardiovascular, women's health, and anti-infection, as well as the development and implementation of clinical science strategies related to Chinese registration.
director of clinical project operations at Roche's Innovation Center in Shanghai and New York until 2016.
previously worked for more than a decade in the research and development departments of New Base Corporation and ShillingA.
degree in Biophysics from Fudan University and completed a Ph.D. in Neurobiology from Rutgers University in the United States.
60% of the information on the drug instructions comes from clinical pharmacological studies.
more than 50 phase I and clinical pharmacological trials before the launch of Bayer's main product, Byretto.
as a laboratory researcher with a non-medical background, being able to move directly into the clinical department for project management may be the most important opportunity of Wan Yuntao's entire career.
"What is your experience in getting into the clinical field?" This is a question that Wan Yuntao has been asked many times by his peers.
answer is that he not only has Chinese good at logic and writing, but also Chinese difficult to confirm communication, management and leadership skills in European and American companies."
Wan Yuntao after graduating from Fudan Biophysics to study for a Ph.D. in neurobiology, before the thesis defense first chose to go to the biopharmaceutical industry to do a few years of molecular biology, pharmacology, drug screening and other work, but also published a lot of articles, walking in the United States and China researchers typical career path, work Wan Yuntao learned that clinical pharmacology department has more in line with their interests in project management.
National out of the countryChinese applying for project management, marketing, and other highly demanding language and leadership jobs in the U.S., both in terms of the outside environment and their own factors, lack favorable conditions, so stay in the lab to do exploratory work, and even mixed with Chinese researchers in the U.S. normal.
therefore, when Wan Yuntao finally got the job of clinical scientist and project manager through his efforts, it was a successful demonstration in the Chinese circle at the time.
compared with the registered clinical trials of domestic generic drugs, the early clinical treatment of new drugs abroad is an extremely complex process.
from the first trial into the human body, until the preliminary conceptual proof that the new drug may be effective I.B. or II.A phase called early exploratory clinical, into phase II.B and III. is a late-stage verified clinical.
in addition to the classic sense of I., II, III. phase of clinical, clinical pharmacology department to do a large number of clinical pharmacological trials, for the post-market drug instructions to provide more than 60% of the use and safety of information. Phase
I. and pharmacological clinical trials include early pharmacodynamics, pharmacogenic dynamics, biouserability comparisons of different dosage forms, interactions with other marketed drugs, special population dose adjustment requirements, comparisons between different populations, and whether the drug is toxic to the cardiovascular system.
it is normal for a new drug to require twenty or thirty clinical pharmacological trials, and Bayer's Bairstill even conducted more than 50 clinical pharmacological trials before it went on sale.
've been in the same industry or company for a few years, and I'll think about what's next that inspires my passion for work, salary benefits are one aspect, and interest and influence are the more important aspects."
wan Yuntao's biggest gain at Shillinga (later acquired by Mercerton) and NewKidt was his involvement in clinical trials of a number of products that later went on sale, including a variety of drugs that have now entered China.
is more important to be exposed to almost all kinds of clinical research, which is difficult to obtain in China's current stage of development experience.
But many people who have worked for established big companies in Europe and America feel the same way: they are like parts on board, and research and development is generally not considered a major part of the engine compared to the sales and commercial sectors.
long time will feel boring and repetitive.
end of 2012, wan Yuntao returned home with the desire to make new drugs in China.
he wants to use his years of knowledge and experience to promote the development of new drugs in China and realize self-worth.
is a regret and pride for Wan Yuntao to leave the new base, which had not yet started research and development in China.
to give up a large number of shares and equity in Xinji is considered by many to be a silly decision, but the desire to use valuable experience to return home as soon as possible to better exert influence can stimulate Wan Yuntao's new enthusiasm for work.
China's early clinical development is just beginning, we must learn from the beginning of the I. period to take into account the final registration of the entire strategic planning, which has numerous details to deal with, to find a lot of ways to solve.
understand that most new drugs fail in the development process, good clinical pharmacological research programs can speed up development and avoid many unnecessary losses.
Roche's Shanghai Innovation Center is one of the few truly China-based research and development centers in multinational companies, from chemical synthesis to bio-laboratories to early clinical development, rather than registering foreign-listed or fast-listed drugs in China.
joined Roche, Wan Yuntao, the director of early clinical operations, was delighted to have the opportunity to participate in the development of innovative integrated clinical development programs in China, Asia, and around the world for new drugs that truly originate in Chinese laboratories, the biggest gain of Wan Yuntao's three years in Shanghai.
three-year term, Roche will move Wan Yuntao from the Shanghai Innovation Center to New York as a result of a global strategic restructuring.
, Wan Yuntao accepted Bayer's invitation to run the entire clinical science department in China, including medical, pharmacological, biomarkers, and clinical operations teams.
the field of therapeutics has also expanded to include cancer, cardiovascular, women's health and many other adaptation certificates in China and Asia Pacific clinical development.
addition, Bayer has a large market share in many traditional products in China, such as aspirin and antibiotics, which require a variety of pharmacological trials in China and around the world to support new adaptation certificates or dosage forms.
responsibility also means that Wan Yuntao will face greater challenges, the absorption of expertise in various product areas is Wan Yuntao's top priority.
years of multinational enterprises, Wan Yuntao's path to promotion has been fast and steady, he believes, as a manager, professional knowledge and management capabilities are half.
and management capabilities are not only reflected in leading a department, but more importantly in having a big picture, understanding coordination with each department, but also understanding the coordination between China and global headquarters.
"Without a medical background and without completing my doctoral thesis, I can run a research and development department with a large number of ph.D.s in medicine and biology due to balanced expertise, strategic planning experience, and intra-company coordination capabilities."
think the work now is very interesting.
" Wan Yuntao said whether to engage in management depends on personality and understanding, there are many people more suitable for scientific research.
"When the career phase of managing an area in a large enterprise has passed, I may want to experience a start-up, which may inspire my passion for work next.
"